October 17, 2026 09:49 am (IST)
Follow us:
Pharma major Lupin completes its acquisition of US-based GAVIS
Mumbai, Mar 9 (IBNS): Pharma major Lupin Limited (Lupin) announced on Wednesday that it has completed its acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS).
Lupin had announced the acquisition on July 23, 2015.
The acquisition enhances Lupin’s scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics.
The US-based manufacturing & research organization of GAVIS will complement Lupin’s Coral Springs, Florida based R&D center for Inhalation, according to the company.
GAVIS’s New Jersey based manufacturing facility also becomes Lupin’s first manufacturing site in the US.
New Jersey based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products.
GAVIS has 62 ANDA filings pending approval with the US FDA and a pipeline of over 65+ products under development. 72% of these filings pending approvals represent niche dosage forms with 18 Para IVs and 8 FTFs products. GAVIS’s pending approvals address a market of over USD 9 billion.
The combined company will have a portfolio of over 120 in-market products, over 185 cumulative filings pending approval and a deep pipeline of products under development for the US.
The acquisition creates the fifth largest pipeline of ANDA filings with the US FDA, addressing a USD 63.8 billion market.
Lupin has 37 First-to-File (FTF) products, which includes 17 exclusive FTF opportunities.
Lupin and GAVIS combined would now have over 45 FTFs.
Commenting on the transaction, Vinita Gupta, Chief Executive Officer, Lupin Limited said, “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as specialty pipeline.”
Head-quartered in Mumbai, Lupin is a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Onion prices set to get relief? Centre sends 440 tonnes to Tripura ahead of festive season
Fri, Oct 16 2026
12 nations turn to Bengal: ICC hosts diplomats in Kolkata to explore trade and investment opportunities
Thu, Oct 15 2026
Hyundai announces $15.5 billion India investment plan through 2032: Here's what's coming
Wed, Oct 14 2026
Modi, Anita Anand discuss trade, defence and energy as India-Canada ties gain momentum
Wed, Oct 14 2026
Government approves Fairfax Financial as strategic buyer for 60.72% stake in IDBI Bank
Wed, Oct 14 2026